natgillin/translations-raw huggingface dataset:
For patients who are dosed initially at docetaxel 75 mg/m2 in combination with cisplatin and whose nadir of platelet count during the previous course of therapy is < 25,000 cells/mm3, or in patients who experience febrile neutropenia, or in patients with serious non-haematologic toxicities, the docetaxel dose in subsequent cycles should be reduced to 65 mg/m2. 
V kombinaciji s cisplatinom Bolnikom, ki uvodoma dobijo docetaksel v odmerku 75 mg/m2 v kombinaciji s cisplatinom in imajo v predhodnem ciklusu zdravljenja najmanjše število trombocitov < 25.000 celic/mm3, bolnikom, ki doživijo febrilno nevtropenijo, in bolnikom z resnimi nehematološkimi toksičnimi učinki je treba odmerek docetaksela v naslednjih ciklusih zmanjšati na 65 mg/m2.
Efficacy of docetaxel in the treatment of patients with gastric adenocarcinoma 
Učinkovitost docetaxela pri zdravljenju bolnikov z adenokarcinomom želodca
For combination with ADT and with prednisone or prednisolone (STAMPEDE study), adverse events occurring over the 6 cycles of treatment with docetaxel and having at least 2% higher incidence in the docetaxel treatment arm by comparison to the control arm, are presented, using the CTCAE grading scale. 
Za kombinacijo z ADT in prednizonom ali prednizolonom (študija STAMPEDE) so prikazani neželeni učinki, ki so se pojavili v 6 ciklusih zdravljenja z docetakselom in so imeli v skupini z docetakselom vsaj 2 % večjo pojavnost kot v kontrolni skupini; uporabljena je lestvica stopenj CTCAE.
The name of this medicine is Docetaxel Zentiva. 
To zdravilo se imenuje Docetaxel Zentiva.
Other medicines and Docetaxel Zentiva 
Druga zdravila in zdravilo Docetaxel Zentiva
Docetaxel Zentiva in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck. 
Zdravilo Docetaxel Zentiva je v kombinaciji s cisplatinom in 5-fluorouracilom indiciran za indukcijsko zdravljenje bolnikov z lokalno napredovalim skvamoznoceličnim karcinomom glave in vratu.
The ORR was 59.3% (95% CI: 52.8 - 65.9) in AT arm versus 46.5% (95% CI: 39.8 - 53.2) in AC arm. 
V kraku AT je bil celotni delež odziva 59,3 % (95 % IZ: 52,8 - 65,9) in v kraku AC 46,5 % (95 % IZ: 39,8
Patients who experience febrile neutropenia and/or neutropenic infection should have their docetaxel dose reduced to 60 mg/m² in all subsequent cycles (see sections 4.4 and 4.8). 
Bolnikom, ki se jim pojavi febrilna nevtropenija in/ali nevtropenična okužba, je treba odmerek docetaksela v vseh nadaljnjih ciklusih zmanjšati na 60 mg/m2 (glejte poglavji 4.4 in 4.8).
Metastatic hormone-sensitive prostate cancer The recommended dose of docetaxel is 75 mg/m2 every 3 weeks for 6 cycles. 
Metastatski, hormonsko občutljiv rak prostate Priporočeni odmerek docetaksela je 75 mg/m2 na 3 tedne 6 ciklusov.
Prednisone and dexamethasone 
Prednison in deksametazon
It is important that you read the entire contents of this guide prior to the preparation of the Docetaxel Zentiva infusion solution. 
Pomembno je, da pred pripravo osnovne raztopine zdravila Docetaxel Zentiva ali raztopine za infundiranje zdravila Docetaxel Zentiva v celoti preberete ta navodila.
OTHER Contains anhydrous ethanol (see leaflet) 
DRUGI PODATKI Vsebuje brezvodni etanol (glejte navodilo za uporabo)
• 332 patients (TAX327) who received docetaxel in combination with prednisone or prednisolone (clinically important treatment related adverse events are presented). 
• 332 bolnikih (TAX 327), ki so prejemali docetaksel v kombinaciji s prednizonom ali prednizolonom (predstavljeni so klinično pomembni z zdravljenjem povezani neželeni učinki).
From a microbiological point of view, reconstitution/dilution must take place in controlled and aseptic conditions. 
Z mikrobiološkega stališča mora biti rekonstitucija/redčenje opravljeno v nadzarovanih in preverjenih aseptičnih pogojih.
Myelodysplastic syndrome was reported in 2 of 744 TAC patients (0.3%) and in 1 of 736 FAC patients (0.1%). 
Mielodisplastični sindrom so zabeležili pri 2 od 744 bolnic, ki so prejemale TAC (0,3%), in pri 1 od 736 bolnic, ki so prejemale FAC (0,1%).
TAC = docetaxel, doxorubicin and cyclophosphamide FAC = 5-fluorouracil, doxorubicin and cyclophosphamide CI = confidence interval; ER = oestrogen receptor PR = progesterone receptor a ER/PR-negative or Grade 3 or tumour size >5 cm 
TAC = docetaksel, doksorubicin in ciklofosfamid FAC = 5-fluorouracil, doksorubicin in ciklofosfamid IZ = interval zaupanja, ER = estrogenski receptor PR = progesteronski receptor a negativno ER/PR ali 3. stopnja ali velikost tumorja > 5 cm
Cautions for use in castration-resistant prostate cancer Of the 333 patients treated with docetaxel every three weeks in a prostate cancer study (TAX 327), 209 patients were 65 years of age or greater and 68 patients were older than 75 years. 
Previdnost pri uporabi pri raku prostate, odpornem proti kastraciji Od 333 bolnikov z rakom prostate v študiji, ki so bili zdravljeni z docetakselom vsake tri tedne, je bilo 209 bolnikov starih 65 let ali več, 68 bolnikov pa je bilo starih nad 75 let.
PSA response** at 12 months - N(%) p-valuea* 
Odziv PSA** po 12 mesecih - N (%)
Each vial of concentrate contains 2 ml of ethanol anhydrous (1.58 g). 
Vsaka viala koncentrata vsebuje 2 ml brezvodnega etanola (1,58 g).
Consequently, because of the potential for adverse reactions in nursing infants, breast-feeding must be discontinued for the duration of docetaxel therapy. 
Zaradi možnih neželenih učinkov na dojenčke je treba dojenje med zdravljenjem z docetakselom prekiniti.
Cautions for use in hormone-sensitive prostate cancer Of the 545 patients treated with docetaxel every 3 weeks in a hormone-sensitive prostate cancer study (STAMPEDE), 296 patients were 65 years of age or older, and 48 patients were 75 years of age or older. 
Previdnost pri uporabi pri hormonsko občutljivem raku prostate Od 545 bolnikov, ki so bili v študiji hormonsko občutljivega raka prostate (študija STAMPEDE) zdravljeni z docetakselom na 3 tedne, je bilo 296 bolnikov starih 65 let ali več in 48 bolnikov 75 let ali več.
More patients aged ≥65 years in the docetaxel arm reported hypersensitivity reaction, neutropenia, anemia, fluid retention, dyspnea, and nail changes when compared to the patients aged less than 65 years. 
V skupini, ki je prejemala docetaksel, je o preobčutljivostni reakciji, nevtropeniji, anemiji, zadrževanju tekočine, dispneji in spremembi nohtov poročalo več bolnikov, starih ≥ 65 let, kot bolnikov, mlajših od 65 let.
After 10 years of follow up in study TAX316, acute leukaemia was reported in 3 of 744 TAC patients (0.4%) and in 1 of 736 FAC patients (0.1%). 
Po 10 letih spremljanja v študiji TAX316 so akutno levkemijo zabeležili pri 3 od 744 bolnic, ki so prejemale TAC (0,4%), in pri 1 od 736 bolnic, ki so prejemale FAC (0,1%).
• From a microbiological point of view, reconstitution /dilution must take place in controlled and aseptic conditions and the infusion solution should be used immediately. 
• Z mikrobiološkega stališča mora biti rekonstitucija/redčenje opravljeno v nadzarovanih in preverjenih aseptičnih pogojih in raztopino za infundiranje je treba uporabiti takoj.
If Docetaxel Zentiva concentrate or infusion solution should come into contact with skin, wash immediately and thoroughly with soap and water. 
Če pride koncentrat ali raztopina za infundiranje zdravila Docetaxel Zentiva v stik s kožo, jo je treba takoj in temeljito umiti z milom in vodo.
• Docetaxel 30 mg/m2 administered weekly for the first 5 weeks in a 6 week cycle for 5 cycles. 
• Docetaxel 30 mg/m2 aplicirano tedensko prvih 5 tednov 6 tedenskega cikla, ki se ponovi v 5-ih ciklih.
• 174 and 251 head and neck cancer patients who received docetaxel in combination with cisplatin and 5-fluorouracil (clinically important treatment related adverse events are presented). 
• 174 in 251 bolnikih z rakom glave in vratu, ki so prejemali docetaksel v kombinaciji s cisplatinom in 5-fluorouracilom ( navedeni so klinično pomembni, z zdravljenjem povezani, neželeni učinki).
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu/. 
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila (EMA) http://www.ema.europa.eu/
Based on pharmacokinetic data with docetaxel at 100 mg/m² as single agent, patients who have both elevations of transaminase (ALT and/or AST) greater than 1.5 times the upper limit of the normal range (ULN) and alkaline phosphatase greater than 2.5 times the ULN, the recommended dose of docetaxel is 75 mg/m2 (see sections 4.4 and 5.2). 
Bolniki z okvaro jeter Glede na farmakokinetične podatke o monoterapiji z docetakselom v odmerku 100 mg/m2 je priporočljivi odmerek docetaksela za bolnike, ki imajo transaminazi (ALT, AST ali obe) zvišani nad 1,5-kratno zgornjo mejo normalnega območja (ULN) in alkalno fosfatazo nad 2,5-kratno ULN, 75 mg/m2 (glejte poglavji 4.4 in 5.2).
PSA response** at 6 months - N(%) p-valuea* 
Odziv PSA** po 6 mesecih - N (%)
As the benefit observed in patient with 4+ nodes was not statistically significant on disease-free survival (DFS) and overall survival (OS), the positive benefit/risk ratio for TAC in patients with 4+ nodes was not fully demontrated at the final analysis (see section 5.1). 
Za preživetje brez bolezni (DFS - disease-free survival) in celokupno preživetje (OS - overall survival) ugotovljena korist pri bolnicah z bezgavkami 4+ ni bila statistično značilna, zato končna analiza ni v celoti potrdila pozitivnega razmerja med koristjo in tveganjem TAC pri bolnicah z bezgavkami 4+ (glejte poglavje 5.1).
In case CMO is diagnosed, docetaxel treatment should be discontinued and appropriate treatment initiated (see section 
Ce je diagnosticiran CMO, je treba zdravljenje z docetakselom prekiniti in uvesti ustrezno zdravljenje (glejte poglavje 4.8).
If Docetaxel Zentiva concentrate or infusion solution should come into contact with mucous membranes, wash immediately and thoroughly with water. 
Če pride koncentrat ali raztopina za infundiranje zdravila Docetaxel Zentiva v stik s sluznicami, jih je treba takoj in temeljito umiti z vodo.
There is no relevant use of Docetaxel Zentiva in the paediatric population in the indications breast cancer, non-small cell lung cancer, prostate cancer, gastric carcinoma and head and neck cancer, not including type II and III less differentiated nasopharyngeal carcinoma. 
Zdravilo Docetaxel Zentiva ni primerno za uporabo pri pediatrični populaciji za indikacije rak dojke, nedrobnocelični pljučni rak, rak prostate, karcinom želodca in rak glave in vratu, ne vključujoč manj diferenciiran nazofaringealni karcinom tipa II oz. III.
• Then, inject via a single injection (one shot) into a 250 ml infusion bag or bottle containing either 5% glucose solution or sodium chloride 9 mg/ml (0.9%) solution for infusion. 
• Potem jo vbrizgajte preko ene injekcije (en odmerek) v 250-ml infuzijsko vrečko ali steklenico, ki vsebuje 5 % raztopino glukoze ali raztopino natrijevega klorida 9 mg/ml (0,9 %) za injiciranje.
You must not breast-feed while you are treated with Docetaxel Zentiva. 
Med zdravljenjem z zdravilom Docetaxel Zentiva ne smete dojiti.
Docetaxel Zentiva contains ethanol (alcohol) 
Zdravilo Docetaxel Zentiva vsebuje etanol (alkohol).
Each vial of concentrate contains 4 ml of ethanol anhydrous (3.16 g). 
Ena viala koncentrata vsebuje 4 ml brezvodnega etanola (3,16 g).
The severity of adverse events of Docetaxel Zentiva may be increased when Docetaxel Zentiva is given in combination with other chemotherapeutic agents. 
Izrazitost neželenih učinkov zdravila Docetaxel Zentiva se lahko poveča, če dobivate zdravilo Docetaxel Zentiva v kombinaciji z drugimi kemoterapevtiki.
In patients treated with docetaxel at 100 mg/m2 as single agent who have serum transaminase levels (ALT and/or AST) greater than 1.5 times the ULN concurrent with serum alkaline phosphatase levels greater than 2.5 times the ULN, there is a higher risk of developing severe adverse reactions such as toxic deaths including sepsis and gastrointestinal haemorrhage which can be fatal, febrile neutropenia, infections, thrombocytopenia, stomatitis and asthenia. 
(ALT, AST ali obe) zvišani nad 1,5-kratno ULN in hkrati zvišano serumsko alkalno fosfatazo nad 2,5kratno ULN, obstaja večja nevarnost hudih neželenih učinkov, kot so smrti zaradi zastrupitve, vključno s sepso in gastrointestinalno krvavitvijo, ki sta lahko usodni, febrilne nevtropenije, okužb, trombocitopenije, stomatitisa in astenije.
The required volume of Docetaxel Zentiva concentrate for solution for infusion must be injected via a single injection (one shot) into a 250 ml infusion bag or bottle containing either 5% glucose solution or sodium chloride 9 mg/ml (0.9%) solution for infusion. 
Potrebno količino koncentrata za raztopino za infundiranje zdravila Docetaxel Zentiva je treba vbrizgati preko ene injekcije (en odmerek) v 250-ml infuzijsko vrečko ali steklenico, ki vsebuje 5 % raztopino glukoze ali raztopino natrijevega klorida 9 mg/ml (0,9 %) za injiciranje.
Docetaxel Zentiva in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with: 
Zdravilo Docetaxel Zentiva je v kombinaciji z doksorubicinom in ciklofosfamidom indiciran za adjuvantno zdravljenje bolnic z:
Patients treated with TCF had a longer time to 5% definitive deterioration of global health status on the QLQ-C30 questionnaire (p = 0.0121) and a longer time to definitive worsening of Karnofsky performance status (p = 0.0088) compared to patients treated with CF. 
Pri bolnikih, zdravljenih s TCF, je bil v primerjavi s tistimi, ki so jih zdravili s CF, daljši tako čas do 5 % trajnega poslabšanja splošnega zdravstvenega stanja po vprašalniku QLQ--C30 (p = 0,0121) kot čas do trajnega poslabšanja stanja zmogljivosti po Karnofskem (p = 0,0088).
TAC = docetaxel, doxorubicin and cyclophosphamide FAC = 5-fluorouracil, doxorubicin and cyclophosphamide CI = confidence interval 
TAC = docetaksel, doksorubicin in ciklofosfamid FAC = 5-fluorouracil, doksorubicin in ciklofosfamid IZ = interval zaupanja, ER = estrogenski receptor
From a microbiological point of view, reconstitution/dilution must take place in controlled and aseptic conditions and the medicinal product should be used immediately. 
Z mikrobiološkega stališča mora biti rekonstitucija/redčenje opravljeno v nadzorovanih in preverjenih aseptičnih pogojih in zdravilo je treba uporabiti takoj.
This regimen is administered every 3 weeks for 4 cycles. 
Ta terapevtska shema se uporablja vsake 3 tedne za 4 cikle.
Severe skin problems such as Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), Acute Generalized Exanthematous Pustulosis (AGEP) have been reported with Docetaxel Zentiva: - SJS/TEN sympoms may include blistering, peeling or bleeding on any part of your skin (including your lips, eyes, mouth, nose, genitals, hands or feet) with or without a rash. 
Med uporabo zdravila Docetaxel Zentiva so poročali o hudih težavah s kožo, kot so StevensJohnsonov sindrom (SJS), toksična epidermalna nekroliza (TEN) in akutna generalizirana eksantemska pustuloza (AGEP): - Med simptomi SJS/TEN so lahko mehurji, lupljenje ali krvavitev na katerem koli predelu kože (tudi na ustnicah, očeh, v ustih, nosu, na spolovilih, dlaneh in stopalih), z izpuščajem ali brez njega.
Docetaxel is an antineoplastic agent and, as with other potentially toxic compounds, caution should be exercised when handling it and preparing its solutions. 
Docetaxel je antineoplastično zdravilo in tako kot pri ravnanju z drugimi potencialno toksičnimi spojinami je tudi med rokovanjem z njim in med pripravo njegovih raztopin potrebna previdnost.
- For the treatment of lung cancer, Docetaxel Zentiva could be administered either alone or in combination with cisplatin. 
- Za zdravljenje pljučnega raka se zdravilo Docetaxel Zentiva lahko uporablja sam ali v kombinaciji s cisplatinom.
Tumour response rate (%) 95% CI p-value* †Stratified log rank test *Threshold for statistical significance = 0.0175 **PSA: Prostate-Specific Antigen 
Stratificiran log-rang test *Prag statistične značilnosti=0,0175 **PSA: prostatični specifični antigen
In the adjuvant treatment of operable node-positive and node-negative breast cancer, the recommended dose of docetaxel is 75 mg/m2 administered 1-hour after doxorubicin 50 mg/m2 and cyclophosphamide 500 mg/m2 every 3 weeks for 6 cycles (TAC regimen) (see also Dose adjustments during treatment). 
Pri dopolnilnem zdravljenju operabilnega raka dojke s pozitivnimi bezgavkami in negativnimi bezgavkami je priporočeni odmerek docetaksela 75 mg/m2, apliciran eno uro po doksorubicinu 50 mg/m2 in ciklofosfamidu 500 mg/m2 vsake tri tedne v 6 ciklusih (TAC režim) (glejte tudi
Docetaxel Zentiva in combination with androgen-deprivation therapy (ADT), with or without prednisone or prednisolone, is indicated for the treatment of patients with metastatic hormonesensitive prostate cancer. 
Zdravilo Docetaxel Zentiva je v kombinaciji z zdravljenjem z deprivacijo androgenov (ADTandrogen-deprivation therapy) s prednizonom oz. prednizolonom ali brez njega, indicirano za zdravljenje bolnikov z metastatskim, hormonsko občutljivim rakom prostate.
The pharmacokinetics of docetaxel, doxorubicin and cyclophosphamide were not influenced by their co-administration. 
Sočasna uporaba docetaksela, doksorubicina in ciklofosfamida ni vplivala na njihovo farmakokinetiko.
1060 patients were randomised to receive either Docetaxel Zentiva 75 mg/m2 administered 1-hour after doxorubicin 50 mg/m2 and cyclophosphamide 500 mg/m2 (539 patients in TAC arm), or doxorubicin 50 mg/m2 followed by fluorouracil 500 mg/m2 and cyclophosphamide 500 mg/m2 (521 patients in FAC arm), as adjuvant treatment of operable node-negative breast cancer patients with high risk of relapse according to 1998 St. Gallen criteria (tumour size >2 cm and/or negative ER and PR and/or high histological/nuclear grade (grade 2 to 3) and /or age <35 years). 
1060 bolnic je bilo naključno razporejenih na prejemanje zdravila Docetaxel Zentiva 75 mg/m2 1 -uro po doksorubicinu 50 mg/m2 in ciklofosfamidu 500 mg/m2 (539 bolnic v kraku TAC), ali na prejemanje doksorubicina 50 mg/m2, ki sta mu sledila fluorouracil 500 mg/m2 in ciklofosfamid 500 mg/m2 (521 bolnic v kraku FAC) kot adjuvantnega zdravljenja operabilnega raka dojke z negativnimi bezgavkami pri bolnicah z velikim tveganjem recidiva po St.-Gallenskih merilih 1998 (velikost tumorja > 2 cm in/ali negativni ER in PR in/ali visoka histološka/jedrna stopnja (2. do 3. stopnja) in/ali starost < 35 let).
G3/4 AST increased G3/4 Blood alkaline phosphatase increased 
zvečanje AST S3/4 zvečanje alkalne fosfataze v krvi S3/4
Docetaxel should be administered when the neutrophil count is  1,500 cells/mm3. 
Docetaksel je treba aplicirati, ko je število nevtrofilcev ≥ 1.500 celic/mm3.
Docetaxel Zentiva in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease. 
Zdravilo Docetaxel Zentiva je v kombinaciji s cisplatinom in 5-fluorouracilom indiciran za zdravljenje bolnikov z metastatskim adenokarcinomom želodca, vključno z adenokarcinomom na gastroezofagealnem prehodu, ki predhodno še niso bili zdravljeni s kemoterapijo za metastatsko bolezen.
- The other ingredients are polysorbate 80, ethanol anhydrous (see section 2) and citric acid. 
- Pomožne snovi so polisorbat 80, brezvodni etanol (glejte poglavje 2) in citronska kislina.
• Induction chemotherapy followed by radiotherapy (TAX 323) MedDRA system organ classes 
• Indukcijska kemoterapija in nato radioterapija (TAX 323) Organski sistemi po
- For the treatment of early breast cancer with or without lymph node involvement, Docetaxel Zentiva could be administered in combination with doxorubicin and cyclophosphamide. 
- Za zdravljenje zgodnjega raka dojke s prizadetostjo bezgavk ali brez prizadetosti bezgavk se zdravilo Docetaxel Zentiva lahko aplicira v kombinaciji z doksorubicinom in ciklofosfamidom.
Headache 
bolečine
In study TAX316 alopecia persisting into the follow-up period after the end of chemotherapy was reported in 687 of 744 TAC patients (92.3%) and 645 of 736 FAC patients (87.6%). 
V študiji TAX316 je alopecija trajala še naprej v obdobju spremljanja po koncu kemoterapije pri 687 od 744 bolnic, ki so prejemale TAC (92,3%), in pri 645 od 736 bolnic, ki so prejemale FAC (87,6%).
Cautions for use in adjuvant treatment of breast cancer There are limited data available in patients > 70 years of age on docetaxel use in combination with doxorubicin and cyclophosphamide. 
Previdnost pri uporabi pri adjuvantnem zdravljenju raka dojke Podatki o uporabi docetaksela v kombinaciji z doksorubicinom in ciklofosfamidom pri bolnicah starih > 70 let je malo.
The recommended dose of docetaxel is 75 mg/m2 every 3 weeks for 6 cycles. 
Priporočeni odmerek docetaksela je 75 mg/m2 na 3 tedne 6 ciklusov.
In this study, 255 patients were randomised to treatment with docetaxel (75 mg/m2 as a 1 hour intravenous infusion every 3 weeks) and capecitabine (1250 mg/m2 twice daily for 2 weeks followed by 1-week rest period). 
V tej študiji so so 255 bolnic randomizirali na zdravljenje z docetakselom (75 mg/m2 v 1-urni intravenski infuziji na 3 tedne) in kapecitabinom (1.250 mg/m2 dvakrat na dan 2 tedna s sledečim 1-tedenskim premorom).
In the docetaxel plus trastuzumab arm, 64% had received a prior anthracycline as adjuvant therapy compared with 55% in the docetaxel arm alone. 
V kraku z docetaxel in trastuzumabom je 64 % bolnikov predhodno dobivalo antracikline kot adjuvantno terapijo; v kraku, v katerem so bolniki dobivali samo docetaksel, je bil ta delež 55 %.
- For the treatment of head and neck cancer, Docetaxel Zentiva is administered in combination with cisplatin and 5-fluorouracil. 
- Za zdravljenje raka glave in vratu se zdravilo Docetaxel Zentiva uporablja v kombinaciji s cisplatinom in 5-fluorouracilom.
LIST OF EXCIPIENTS Excipients: polysorbate 80, ethanol anhydrous (see leaflet for further information) and citric acid. 
Pomožne snovi: polisorbat 80, brezvodni etanol (za dodatne informacije glejte navodilo za uporabo) in citronska kislina.
Docetaxel Zentiva in combination with doxorubicin and cyclophosphamide: adjuvant therapy 
Zdravilo Docetaxel Zentiva v kombinaciji z doksorubicinom in ciklofosfamidom: adjuvantno zdravljenje
More than one vial of Docetaxel Zentiva concentrate for solution for infusion may be necessary to obtain the required dose for the patient. 
Za odmerek, ki ga potrebuje bolnik, je lahko potrebna več kot ena viala koncentrata za raztopino za infundiranje zdravila Docetaxel Zentiva.
• 1312 and 121 patients who received 100 mg/m² and 75 mg/m² of docetaxel as a single agent respectively. 
• 1312 bolnikih, ki so v monoterapiji prejemali 100 mg/m² zdravila docetaksel, 121 pa jih je prejemalo 75 mg/m².
- For the treatment of prostate cancer, Docetaxel Zentiva is administered in combination with prednisone or prednisolone. 
- Za zdravljenje raka prostate se zdravilo Docetaxel Zentiva lahko uporablja v kombinaciji s prednizonom ali prednizolonom.
PHARMACEUTICAL FORM Concentrate for solution for infusion (sterile concentrate). 
FARMACEVTSKA OBLIKA koncentrat za raztopino za infundiranje (sterilni koncentrat) Koncentratje bledorumena do rjavkastorumena raztopina.
- For the treatment of metastatic gastric cancer, Docetaxel Zentiva is administered in combination with cisplatin and 5-fluorouracil. 
- Za zdravljenje metastatskega raka želodca se zdravilo Docetaxel Zentiva uporablja v kombinaciji s cisplatinom in 5-fluorouracilom.